MannKind Corporation

MannKind Corporation designated its Danbury, Connecticut manufacturing and R&D facility as its new corporate headquarters, adding more than 50 jobs in 2023 and planning further expansions.

MannKind Corporation has scaled-up operations for increased production capacity of Tyvaso DPI, representing a $60 million investment. Construction is ongoing to build out new manufacturing space in Danbury, Connecticut.

MannKind Corporation has agreed to acquire the V-Go wearable insulin delivery device from Zealand Pharma for $10 million plus sales-based milestones and inventory costs, expanding its diabetes portfolio.